Immix Biopharma Investor Presentation Deck

Cell Therapy Platform HIM 3 Key Elements Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical Proprietary EXPAND technology Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability Atomized, Novel Binding Scaffold Generation Engine Allows us to make the correct binding for every molecule N-GENIUS PLATFORM NXC-201 CAR-T CELL NXC-301 CAR-T CELL BCMA EXPRESSING CANCER CELL NXC-401 CAR-T CELL NXC-201 CAR-T CELL CANCER CELL NXC-301 CAR-T CELL CANCER CELL Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. NXC-401 CAR-T CELL Produced NXC-201, NXC-301, NXC-401 BCMA Surface Expression 1 NXC-201 BCMA I Chimeric Antigen Receptor I (CAR) I I Surface Expression I. NXC-301 I Proprietary Chimeric I Antigen Receptor I (CAR) I I Surface Expression. NXC-401 Proprietary I Chimeric Antigen Receptor I (CAR) ● NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) targeting B-cell maturation antigen (BCMA) ● ● ●●● IMMİX S BIOPHARMA NXC-301 is a next-generation CAR-T with a proprietary target. Indications: High Complete Response Rates in AL Amyloidosis and Multiple Myeloma ● First Outpatient CAR-T: Short CRS duration (median 1 day) starting on day 0 4% neurotoxicity Acute lymphocytic leukemia (ALL) Large B-Cell Lymphoma (LBCL) Mantle cell lymphoma (MCL) NXC-401 is a next-generation CAR-T with a proprietary target. Indications: Acute Myeloid Leukemia (AML) 61

View entire presentation